EA
CDTX

Emerald Acquisition’s Cidara Therapeutics CDTX Stock Holding History

Emerald Acquisition’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$185K Sell
805
-82
-9% -$18.9K ﹤0.01% 2707
2016
Q2 		$183K Buy
+887
New +$215K ﹤0.01% 2747

Other funds holding CDTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Emerald Acquisition's CDTX Position: Q3 2016 in Review

Emerald Acquisition reduced its Cidara Therapeutics (CDTX) stake by 9.2% in Q3 2016, selling an estimated $18.9K and leaving 805 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #2707.

Emerald Acquisition first reported a position in CDTX in Q2 2016 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold CDTX as of Q3 2016.

  • Emerald Acquisition held 805 shares of Cidara Therapeutics worth $185K as of Q3 2016.
  • Emerald Acquisition sold 82 Cidara Therapeutics shares in Q3 2016, an estimated $18.9K.
  • Cidara Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2707 holding.
  • Emerald Acquisition first reported a position in Cidara Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.